Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Mydecine Innovations Group Inc
MYCOFMydecine Innovations Group Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. Its lead product drug candidates include MYCO-005. The company also develops MYCO-006 and MYCO-007. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada. Address: 1075 West Georgia Street, Vancouver, BC, Canada, V6E 3C9
Analytics
Objectif de Cours de WallStreet
–Ratio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés MYCOF
Analyse des dividendes MYCOF
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes MYCOF
Valorisation des titres MYCOF
financières MYCOF
Résultats | 2019 | Dynamique |